Targeting RECQL4 in hepatocellular carcinoma: from prognosis to therapeutic potential.

BMC Med Genomics · 2025 · PMC11863661 · PMID 40001159

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

highly significantp < 0.001actually significant

Furthermore, RECQL4 levels between stage G1 and stages G3 and G4, as well as between stage G2 and stage G3, exhibited highly significant differences ( p < 0.001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.